

DCAT

TOP
Industry
NEWS

*BUSY WEEK? Here are the
TOP INDUSTRY NEWS stories
you might have missed, as
selected by DCAT Editorial
Director Patricia Van Arnum.*

Patheon
A HEALTHIER WORLD. DELIVERED.

Executive insights. Delivered.

Learn more

1. [J&J to Acquire Actelion in \\$30-Billion Deal and Plans R&D Spin-Out](#)

Johnson & Johnson (J&J) has agreed to acquire the Swiss biopharmaceuticals firm, Actelion, in a deal valued at \$30 billion and will spin out Actelion's research and development unit as a standalone company in which J&J will hold a minority stake. [Read More](#)

2. [BMS, Merck & Co. in \\$625-Million Settlement for Keytruda Patent Litigation](#)

Bristol-Myers Squibb and Ono Pharmaceutical Company have signed a \$625-million global patent license agreement with Merck & Co. to settle all patent-infringement litigation related to Merck's anti-cancer drug, Keytruda (pembrolizumab). Merck will also pay ongoing royalties on global sales of Keytruda. [Read More](#)

3. [Lilly to Cut 485 Sales Jobs Across US Operations](#)

Eli Lilly and Company plans to cut 485 sales positions across its operations in the US, including its US Bio-Medicines Business Unit in Indianapolis, Indiana, as the result of a failed late-stage clinical trial for its Alzheimer's disease drug candidate, solanezumab. [Read More](#)

4. [Valeant To Sell Dendreon to China's Sanpower for \\$820 Million](#)

Valeant Pharmaceuticals has agreed to sell Dendreon Pharmaceuticals to the Sanpower Group, a business conglomerate based in Nanjing, China, for \$819.9 million, which includes Dendreon's prostate cancer vaccine, Provenge (sipuleucel-T) and certain other assets. [Read More](#)

5. [Endo Restructures Corporate and Brand Pharma R&D Functions...](#)

Endo International has initiated a restructuring program primarily impacting its corporate functions and branded pharmaceutical research and development functions in Malvern, Pennsylvania and Chestnut Ridge, New York, which includes a workforce reduction of approximately 90 full-time positions. [Read More](#)

6. [...and Endo, FTC Agree to Settle Pain Med Litigation](#)

Endo International and the US Federal Trade Commission have filed a joint motion in federal court for a proposed 10-year stipulated order to resolve litigation involving two of Endo's pain medications. [Read More](#)

7. [Celgene to Acquire Autoimmune Drug Company in \\$775-Million Deal](#)

Celgene has agreed to acquire Delinia, a San Francisco-based biopharmaceutical company specializing in autoimmune disease therapies, in a deal worth \$775 million. [Read More](#)

8. [EMA, FDA Accept BI's Filing for Biosimilar of AbbVie's Humira](#)

The FDA and the European Medicines Agency have accepted for review Boehringer Ingelheim's adalimumab biosimilar candidate to AbbVie's Humira (adalimumab), AbbVie's top-selling drug with 2015 global sales of \$14 billion. [Read More](#)

9. [EDQM Issues Update on Elemental Impurities](#)

The European Directorate for the Quality of Medicines and Healthcare (EDQM) has provided an update to revisions to the *European Pharmacopoeia* based on the implementation of guidelines by the International Conference on Harmonization for elemental impurities. [Read More](#)

10. [Pharma, Gates Foundation Form Global Vaccine Partnership CEPI](#)

The Bill & Melinda Gates Foundation, the Wellcome Trust, and the governments of Germany, Japan, and Norway have pledged \$460 million to the Coalition for Epidemic Preparedness Innovations, a global private-public partnership for developing new vaccines for infectious diseases, which includes support from the pharmaceutical industry. [Read More](#)

About Top Industry News

The DCAT organization recognizes its members have minimal time to keep up with the continuous flow of news covering this dynamic industry. To help ensure our members never miss the most important stories impacting the global pharmaceutical manufacturing industry, we will deliver each Friday, the week's Top Industry News, as selected by DCAT Editorial Director Patricia Van Arnum.



The Drug, Chemical & Associated Technologies Association (DCAT) is a not-for-profit, global business development association whose unique membership model integrates both innovator and generic drug manufacturers and suppliers of ingredients, development and manufacturing services, and related technologies. We are committed to provide programs, events and services that help our members meet their business objectives, expand their network of customers and suppliers, and gain insight into industry trends, markets, and those issues impacting pharmaceutical development and manufacturing.



One Union Street, Suite 208, Robbinsville, NJ 08691
Local: +1.609.208.1888 · Toll Free: +1.800.640.DCAT(3228) · Fax: +1.609.208.0599

www.dcat.org

Drug, Chemical, & Associated Technologies Association, One Union Street,
Suite 208, Robbinsville, NJ 08691

[SafeUnsubscribe™ {recipient's email}](#)

[Forward this email](#) | [Update Profile](#) | [About our service provider](#)

Sent by dcatnews@dcat.org